A phase I study of salmeterol/fluticasone-propionate administered via metered dose inhaler (MDI) for treatment of asthma and chronic obstructive pulmonary disease

Trial Profile

A phase I study of salmeterol/fluticasone-propionate administered via metered dose inhaler (MDI) for treatment of asthma and chronic obstructive pulmonary disease

Planning
Phase of Trial: Phase I

Latest Information Update: 04 Dec 2014

At a glance

  • Drugs Salmeterol/fluticasone propionate (Primary)
  • Indications Asthma; Chronic obstructive pulmonary disease
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top